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Currently, autologous bone grafting represents the clinical gold standard in orthopaedic surgery. In certain cases, however,
alternative techniques are required. The clinical utility of stem and stromal cells has been demonstrated for the repair and
regeneration of craniomaxillofacial and long bone defects although clinical adoption of bone tissue engineering protocols has been
very limited. Initial tissue engineering studies focused on the bone marrow as a source of cells for bone regeneration, and while
a number of promising results continue to emerge, limitations to this technique have prompted the exploration of alternative cell
sources, including adipose and muscle tissue. In this review paper we discuss the advantages and disadvantages of cell sources
with a focus on adipose tissue and the bone marrow. Additionally, we highlight the relatively recent paradigm of developmental
engineering, which promotes the recapitulation of naturally occurring developmental processes to allow the implant to optimally
respond to endogenous cues. Finally we examine efforts to apply lessons from studies into different cell sources and developmental
approaches to stimulate bone growth by use of decellularised hypertrophic cartilage templates.
1. Introduction
Bone tissue is capable of spontaneous self-repair, with no
scarring, generating new tissue that is all but indistinguish-
able from surrounding bone. However, in certain circum-
stances, the defect is too large (due to tumour resection,
osteomyelitis, atrophic nonunions, and periprosthetic bone
loss), or the underlying physiological state of the patient
impairs natural healing (osteoporosis, infection, diabetes,
and smoking) necessitating intervention. Autologous bone
grafting is today the gold standard for bone repair, although
the costs of this approach are considerable due to the
additional surgical procedures required to harvest the bone
material, the consequent donor sitemorbidity [1], and the risk
of infection and complications. Additionally, this approach is
hampered by the limited amount of donor material available
for transplantation which can be prohibitive when dealing
with large defects. To resolve these issues, both allograft- and
xenograft-based strategies have been proposed; however the
risk of rejection in the former and of zoonoses in the latter has
reduced their clinical impact. Bone tissue engineering (BTE)
is an alternative strategy that has been explored to fill the
clinical need for autologous bone transplantation.
Almost half a century has passed since the demonstra-
tion that ectopic transplantation of bone marrow and bone
fragments leads to the formation of de novo bone tissue
which, when transplanted subcutaneously, is later filled with
bone marrow [2, 3]. Nowadays, the notion that a set of cells
present in the bone marrow stroma can be cultured in vitro
and can regenerate fully functional bone organs in vivo is
well accepted, although the identity and precise molecular
characterisation of the cell population responsible are still
a matter of study and debate (reviewed in [4, 5]). The ex
vivo expansion and manipulation of stromal cells derived
from various sources form the foundation of the majority of
current bone tissue engineering attempts to meet the clinical
demands for bone regeneration and repair.
Over the last 50 years, the BTE field has made significant
advances towards overcoming the limitations of conventional
methods which is particularly relevant when an underlying
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pathology calls for alternatives to the status quo. Clinically,
several examples of successful application of tissue engi-
neering techniques to bone reconstruction exist within the
literature [6–8]; however, on the whole, advances in basic
science have not translated well into significantly increased
clinical application. The reasons are, in part, financial, but
additional problems such as low efficiency of differentiation,
intrapatient variability [9], the risk of ectopic bone growth
[10], possible transformation [11], or epithelial to mesenchy-
mal transition coupled with an incomplete understanding of
the underlying pathways which are being manipulated with
factors, such as transforming growth factor 𝛽 (TGF-𝛽) and
bonemorphogenic proteins (BMPs) [10, 12–15], certainly play
a role.
Minimal clinical adoption has prompted the exploration
and adaptation of alternative methods including the use of
stromal cells from nonbone sources [16, 17], most commonly,
adipose tissue [8, 18–20], but also muscle [17]; the develop-
ment of new tissue engineering paradigms in which the focus
is shifted from “cells + cytokines” to the engineering and in
vitro optimisation of treatments as a means to support in vivo
developmental processes by harnessing innate developmental
pathways [21–26]; and finally, attempts to create “off-the-
shelf” products to stimulate the regeneration of bone through
adoption of developmental engineering principles [27–29].
The various merits of these points will be the focus of this
review.
2. Cell Source
While the bone marrow (BM) represents the most well-
documented source of cells for the regeneration and repair
of skeletal tissues, a wide variety of alternatives, including
adipose tissue (AT) [18, 19], muscle [17], umbilical cord blood
[16, 30], umbilical cord Wharton’s jelly [31], dental pulp
[32], and periosteal tissue [33], have been explored for bone
regeneration. For the purpose of this review, we will focus on
two sources of stromal cells which have been the subject of the
greatest number of studies in recent years and which are both
attractive for different reasons, namely, the bone marrow and
adipose tissue.
2.1. From Bone Fragment Transplants to Identification of the
Skeletal Stem Cell. In the late 1960s it was shown that bone
fragments and/or suspensions of cultured bonemarrow cells,
when ectopically implanted inmice, rats, rabbits, and guinea-
pigs, were capable of forming bone composed of donor
osteoblasts, osteocytes, and bone marrow stroma adipocytes,
which was capable of attracting host haematopoietic cells
to the bone marrow stroma [3, 34]. It was later shown
that, by plating cultured, nonhaematopoietic, bone marrow
suspensions at lowdensity, a specific subpopulation of plastic-
adherent fibroblast-like cells could be isolated that were
responsible for single-cell colony formation, the colony-
forming unit-fibroblast (CFU-f) [35, 36]. It was clear that a
nonhaematopoietic cell population within the bone marrow
was responsible for the in vivo regeneration and spatial
organisation of skeletal tissues.
In the early 1990s Arnold Caplan’s group showed that rat
bone marrow-derived mesenchymal cells, purified through
plastic adherence, could be passaged multiple times, demon-
strating self-renewal (albeit in vitro), and were still capable
of differentiation into cells of the skeletal system in vivo,
namely, osteoblasts and chondrocytes, and coined the term
“mesenchymal stem cell” [37, 38]. Further studies in humans
confirmed the ability of a rapidly dividing subset of bone
marrow-derived stromal cells (BMSCs) to differentiate into
skeletal lineages (bone, cartilage, adipocytes, and marrow
stroma) [39, 40] in a hierarchical manner and to undergo
in vitro self-renewal, giving rise to secondary colonies upon
replating at the clonal level [41, 42].
In vivo demonstration of BMSC stem cell characteris-
tics, namely, self-replication and multipotency, came with
the description of CD146+/MCAM (melanoma cell adhe-
sion molecule) [43] and nestin+ [44] perivascular adventi-
tial cells. Transplantation of single CFU-f-derived CD146+
colonies implanted in hydroxyapatite-tricalcium phosphate
(HA-TCP) carrier in a fibrin gel in mice resulted in the
formation of ossicles with a functional bone marrow popu-
lated by murine (host) haematopoietic cells and endothelium
with human CD146+ adventitial cells lining the sinusoidal
vessels, which were capable of generating secondary CFU-
fs in vitro [43]. Similarly, implantation of nestin+ clonal cell
spheres harvested two months after subcutaneous implanta-
tion in mice resulted in the generation of secondary ossicles
with donor-derived osteoblasts and nestin+ cells after eight
months [44]. Nestin+ cells were shown to spatially associate
with haematopoietic stem cells (HSCs), to express high levels
of HSC maintenance genes, and to influence HSC homing
in addition to differentiation into osteochondral lineages; in
addition they were shown to be entirely responsible for the
clonogenic activity of the CD45− cell fraction [44]. More
recently, evidence for a skeletal stem cell (SSC) resident in
the BM reticulum, characterised by expression of the BMP
antagonist Gremlin-1, has emerged [45] which has challenged
previous ideas about the identity of the SSC, particularly the
use of nestin as an appropriate SSC marker and the develop-
mental origins of BM adipocytes [45], although it is possible
that these conflicting data may be due to different active
populations of SSCs during different phases of development
[45, 46].
2.2. Clinical BTE Application of BMSCs. Practically, BMSCs
are applicable to large bone defects in both small [47]
and large [48, 49] animals when implanted within hydrox-
yapatite-based scaffolds. Experimental evidence for the abil-
ity of BMSCs to repair bone defects was given crucial clinical
support in 2001, when Quarto and colleagues published
results obtained in three patients with various long bone
defects [6]. BMSCs were isolated and expanded ex vivo
under the stimulation of specific growth factors [50] before
implantation on hydroxyapatite (HA) scaffolds tailored to
the dimensions of each bone defect. It was reported that
“all patients recovered limb function” and that, within two
months of implantation, good integration with the recipient
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bone was observed [6]. Shortly afterwards, the use of autolo-
gous BM encased within a titanium cage with bone mineral
blocks for reconstructive mandibular reconstruction was
reported [51]. The scaffold was implanted in the dorsal latis-
simus dorsi muscle for seven weeks allowing for growth and
vascularisation before transplantation of the bone-muscle
flap.This method, while slow, avoided the creation of a donor
site bone defect. More recently, the successful treatment of
long bone defects in four patients was reported after 6-7
years of follow-up [52]. As of the time of writing, 33 clinical
trials (https://www.clinicaltrials.gov/) are registered for the
use of BMSCs, only two of which are directed towards bone
repair or regeneration: NCT02177565 is investigating the use
of in vitro expanded autologous BMSCs for the treatment
of nonunions although at the time of writing the trial has
been completed, but no results are posted. The multicentre
ORTHO-2 trial for the “Evaluation of Mesenchymal Stem
Cells to Treat AvascularNecrosis of theHip” (NCT02065167),
as part of the REBORNE (regenerating bone defects using
new biomedical engineering approaches) programme, for
the use of autologous BMSCs for the treatment of necrosis
of the femoral head got underway in late 2014; however
no results are available as of yet. The paucity of clinical
trials investigating the potential of autologous BMSCs for
bone repair and regeneration likely reflect hurdles to clinical
use, be it GMP cell expansion, interpatient variability, or
the difficulty in enrolling sufficient patients, notwithstanding
positive results previously reported [6].
2.3. Bone from Fat: Successful Application of Fat-Derived Cells
for BTE. Concurrent with studies illustrating the clinical
application of BMSCs for bone regeneration, it was demon-
strated that human processed lipoaspirate (PLA) cells, iso-
lated from liposuction procedures, could be induced to differ-
entiate into osteogenic, adipogenic, chondrogenic, and myo-
genic lineages through incubation in specific media [18] and
showed increased expression of core-binding factor alpha-
1 (CBFA-1)/runt-related transcription factor 2 (RUNX2),
osteocalcin, and alkaline phosphatase, following induction in
osteogenic medium [19]. These results were paralleled by a
30-fold increase in matrix calcification suggesting the appli-
cability of adipose tissue-derived stromal cells (ADSCs) to
bone repair.Multiple studies into the BTE potential of ADSCs
were published in the following years both in vitro [16, 53, 54]
and in vivo in animal models [20, 55–58] and in humans
[7, 8, 59].Many studies noted not only the greater accessibility
of ADSCs, but also the greater number of progenitors in
lipoaspirates (100 times the number of progenitors compared
to the same volume of BM) [60]. Animal studies not only
revealed the potential of ADSCs to generate functional bone
[16, 20, 56, 61] but also demonstrated additional advantages
over bonemarrow derived counterparts, such as a propensity
for greater proliferation [62] and CFU-f formation [16, 58],
reduced senescence in vitro [16, 54], and greater production of
CXCL 12 [57], the so-called HSC-niche factor [63], and lower
risk of malignant transformation [11].
The clinical application of ADSCs for BTE is followed
rapidly with a case report of maxillary reconstruction. GMP-
expanded ADSCs were induced with BMP-2, seeded onto a
beta-tricalcium phosphate (𝛽-TCP) scaffold, and implanted
within the patient’s rectus abdominis muscle. Eight months
later, the scaffold and surrounding titanium cage were trans-
ferred to the patient’s jaw. Vascularised living bone tissue
was reported and dental implants were successfully made
four months later [7]. In situations where little autologous
bone is available, as in children, adipose tissue represents a
good potential source of cells. Lendeckel and colleagues [59]
reported the use of ADSCs to supplement autologous bone
material in the successful repair of calvarial defects in a 7-
year-old patient: bone grafts were mixed with fibrin glue and
ADSCs were injected into the grafts in a single operational
procedure. Applying similar techniques, 13 patients were
treated with cultured ADSCs implanted on either bioactive
glass (BAG), 𝛽-TCP, or “ChronOS” (Mathys, Switzerland)
synthetic 𝛽-TCP granules, with or without the addition of
BMP-2. In 10 of the 13 cases successful bone integration and
repair was reported [8].
The unfractioned lipoaspirate, or stromal vascular frac-
tion (SVF), “consists of a heterogeneous population of cells
that includes not only adipose, stromal, and hematopoietic
stem and progenitor cells, but also endothelial cells, erythro-
cytes, fibroblasts, lymphocytes, monocyte/macrophages and
pericytes, among others” [64]. Using the SVF, an autogenic
osteogenic graft prepared using a perfusion bioreactor system
could be ready for implantation in 5 days, as compared to 3
weeks when using bone marrow derived cells [65]. Addition-
ally, the greater proliferative capacity of SVF cells [58, 62] and
the presence of vasculature-forming endothelial cells [65, 66]
may permit their application to intraoperative procedures [17,
67], reducing operative duration and associated morbidity.
Animal studies suggest that SVF holds merit as a viable BTE
cell source [67, 68].
2.4. Definition of a Multipotent Mesenchymal Stromal Cell
Population. Owing to doubts about the validity of compar-
isons made between different studies using stromal cells
from different tissues, the International Society for Cellular
Therapy (ISCT) outlined a set of minimal criteria for the
identification of multipotent mesenchymal stromal cells,
stipulating that the cells must be plastic-adherent, express
CD105 (endoglin), CD73 (ecto-5󸀠-nucleotidase), CD90 (Thy-
1) and lack expression of CD45 (lymphocyte common
antigen), CD34 (CD34+ cells were included in updated
version of the statement to include SVF cells [64]), CD14,
or CD11b (ITGAM), CD79a (MB1), or CD19 and HLA-DR
surface molecules, and, finally, differentiate to osteoblasts,
adipocytes, and chondroblasts in vitro [69].
A number of problems exist with these criteria: the use
of plastic adherence as a requirement encourages the use
of two-dimensional (2D) culture which has been associated
with a loss of cell motility, proliferative activity [70], and
osteogenic potential [71, 72]. The 2D environment alters
cellular behaviour and may negatively affect both ADSC
and BMSC development [73]. Furthermore, not all osteo-
progenitors are necessarily adherent to culture dishes, BM-
derived mesenpheres, for example [44]. The stipulation that
in vitro cultured cells can be forced to differentiate into
chondrocytes, osteocytes, and marrow adipocytes, following
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prolonged, constant concentrations of differentiation factors,
is at odds with the variation over time in the levels of these
agents in vivo (reviewed in [74]) and results suggesting that
resident stem cell populations have an intrinsic tendency
to differentiate into the lineages of their resident tissue [58,
75–77], perhaps through epigenetic programming [75]. This
last point is exemplified by results indicating that skeletal
genes are upregulated in undifferentiated BMSCs that are
unchanged in ADSCs [78] and the same BMSCs require no
induction to form bone/bone marrow in vivo [78], while
other sources of stromal cells require chemical [18, 19, 79]
or genetic [17] induction. This may be significant when one
considers the potential effects of long-term exposure of cells
to inductive agents; BMP-2, for example, has been linked
to the malignant transformation of breast cells [12], ectopic
bone growth [10], and neurotoxicity [13]. Considerationmust
be given also to the methods by which differentiation into
the three skeletal lineages is assessed; initial studies which
reported the successful differentiation of non-BM cells into
skeletal lineages did so on the basis of one histological stain
per lineage. The combined use of histology, surface markers,
multiple gene analysis, or proteomics would make for a more
robust analysis of cellular developmental state (as used by
Murata et al. [20]). Lastly, while many studies have found
the ISCT marker profile between ADSCs and BMSCs to be
identical [78, 80], others have noted significant differences
in the two cell populations particularly in the expression of
CD106 [16, 64] and CD36 [64]. It seems clear that ADSC and
BMSC are far from identical: a salient point is their differing
propensity to form cartilage, bone, and fat tissues, possibly
due to epigenetic factors [75]. Therefore the interchangeable
use of “MSC” to describe both (as well as stromal cells derived
from other tissues) is inaccurate, and its discontinuation has
been called for [81, 82]. An indication of the cell source is
crucial; thus “BMSC” and “ADSC” or term or a similar term
ought to be used to clarify the tissue of origin at the very least.
2.5. BM and AT: Promising Cell Sources for BTE, but Not
without Hurdles to Clinical Use. The demonstrated benefit of
BMSC-based BTE [6, 51, 52] is backed up by a number of
recent studies proposing candidates for the skeletal progen-
itor [43–45, 83] and others showing the innate osteochondral
propensity of BMSCs [53, 78, 84, 85] (Table 1). The ability of
the SSCwithin the BMSC population to generate a functional
bone/bone marrow organ [4, 43, 84] places them as the
prime candidate for regeneration of bone tissues. If the native
physiological state of bone tissue is to be recreated then the
ability to form the HME, where the SSC and HSC reside, is of
paramount importance.
The clinical success of ADSC-basedmethods [7, 8, 20, 56]
(Table 1) suggests that nonbone tissues can indeed be coaxed
into forming mature bone. The lack of evidence for HME-
support [86] casts doubt on the use of cells from this source,
but given the evidence that they can be used to achieve
successful bone repair coupled with the ease of collection
and abundance (cf. BMSCs) [60, 72] the speed at which
they can be prepared and replaced into the defect site [87]
and their resistance to senescence [54, 88] and malignant
transformation [89] ADSCs hold great potential for BTE.
Challenges facing the BTE field include the elucidation
of the mechanisms underlying the developmental pathways
involved in bone regeneration/repair and substantial task of
bringing BTE technologies to the clinic at a cost that is on a
par with current techniques.
3. Developmental Engineering
Initial hopes for the application of tissue engineering to
the repair and regeneration of bone have not yet come
to fruition. Unfortunately, the unmet clinical need which
generated the enthusiasm surrounding TE in the 1990s [90]
persists today [60]. Developments, particularly in animal
models (see previous section), have advanced the field, but
the resulting clinical impact has been limited.
3.1. Advancing the “Cells + Cytokines” Model of BTE. Tra-
ditionally, BTE has focused on tissue replacement through
the in vitro/ex vivo generation of implants which effec-
tively mimic the mature tissue as it is found in the
adult. This has been achieved through the use of different
cells, scaffold materials, and soluble factors to create a
mechanical/biochemical profile that is similar to the tis-
sue it is designed to replace [90]. Scaffolds give physi-
cal strength, durability, malleability, and three-dimensional
structure, allowing for custom-sized implants with specific
mechanophysical characteristics.The choice of scaffold is not
insignificant as the architecture, rigidity, and biochemical
properties can modulate cell differentiation. Different scaf-
fold materials can be combined [91] or supplemented with
growth factors such as BMPs [10]. Various combinations of
growth factors are routinely used to guide cell differentiation
towards the desired phenotype; however the use of a limited
number of factors is a long way from the complexity seen
in vivo [60, 92]. Bioreactors using controlled perfusion of
media through three-dimensional scaffolds recapitulate, to
some degree, mechanical [93, 94] and hydrostatic forces
[95], representing a step towards replicating the tempospatial
complexity of the in vivo microenvironment, something
which may well be impossible to recreate in vitro.
In recent years a number of laboratories have adopted
strategies which do not conform to the standard “cells +
scaffold + cytokines” approach that typifies the majority of
BTE studies, instead opting for a “developmental engineer-
ing” (DE) approach [21, 22]. Just as the transition from
two-dimensional to three-dimensional in vitro cell culture
[72] recognised the merits of more faithfully replicating
in vivo spatial relationships [70], the transition from TE
to DE attempts to take into account the complexity of in
vivo developmental processes and to incorporate features
found therein for the design and generation of developmental
templates.
3.2. Key Concepts of Developmental Engineering. Recently,
Lenas et al. [21, 22] described a fusion of engineering prin-
ciples and concepts from developmental biology, which they
termed “developmental engineering.” The authors outlined
the utility of applying concepts such as path-dependence,
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robustness, and modularity, to the manufacture of tissue
grafts/implants. Robustness, within the context of devel-
opmental processes, refers to the ability of a system to
function consistently despite external fluctuations. A robust
developmental mechanism would therefore be able to cope
with a degree of dissimilarity between the native tissue and
the implant. A problem encounteredwhen trying to gauge the
characteristics necessary for successful stimulation of native
repair processes is one of sensitivity; the basic tools and the
limited sensitivity of currently applied methods means we
are not yet able to predict whether a certain implant will
function effectively, leading tomuch trial and error. However,
the modularity of many developmental processes permits ex
vivo experimentation to determine optimal conditions and
timing for implantation to achieve the best results in vivo
[84, 96]. Additionally, ex vivo experiments can be used to
identify markers for the successful completion of multistage
developmental processes [22, 97]. In this fashion, the progress
of the implant can be monitored, in vivo, through the
stages of development, highlighting where problems lie and
thus where refinement is needed. The successful completion
of each step of development sets the stage for the next
step, providing optimal conditions. This concept, rooted in
economics, law [98], and biology, is called path-dependence
and describes a situation where the outcome of one process
directly influences the effectiveness of a successive process.
Thus, one process acts as a check-point for the correct
completion of the previous step, and at the same time
completion of the previous step sets the stage for the following
stages. In the context of bone regeneration, this is exemplified
by hypertrophic chondrocytes which act as a natural scaffold
for osteogenesis as well as secreting factors which orchestrate
the differentiation of osteoblasts from perichondrial cells, as
well as themineralisation and vascularisation of the neo-bone
tissue, restoring normoxic conditions required for optimal
bone growth and bringing vital materials [99]. This concept
has experimental support; hypertrophic chondrocytes have
been shown to stimulate bone regeneration in vivo, while
lesser developed tissues were not as effective in stimulating
the formation of bone tissue, likely reflecting the path-
dependence of this process [28, 84]. Indeed, BMSCs have
been demonstrated to follow the endochondral route when
chondrogenically primed and implanted in a vascularised
tissue [25].The use of a hypertrophic differentiation medium
accelerates and makes the process more efficient.
Instead of aiming to phenocopy the adult tissue-state,
researchers are drawing on the work of developmental biol-
ogy, which states that “normal tissue healing in the adult
involves progressive remodelling of pre-existing tissue struc-
tures” [90] to generate grafts that recapitulate the immature
tissue-state. By implanting the precursor state of a tissue, or
“organ germ” [57, 100], elements of the implant can interact
with natural developmental cues to regulate differentiation
and growth and to provide cues for cell invasion, remod-
elling, and revascularisation in the correct spatiotemporal
context. In this manner we might overcome one of the
greatest challenges facing TE, that is, effectively mimicking
the complexity of natural developmental processes, thereby
leading to formation of an authentic mature tissue.
Considering that the vast majority of bones develop
through endochondral ossification, an endochondral ap-
proach to bone regeneration is now considered “develop-
mental engineering.” However, the endochondral approach
per se does not make “developmental engineering” a bone
regeneration strategy. In fact, flat bones of the head develop
through intramembranous ossification.
3.3. Recapitulation of Endochondral Ossification through
Chondrogenic Differentiation. Historically, TE has directed
the formation of neo-bone through the intramembranous
route relying on the presence of mineralised substrate
scaffolds to initiate bone growth through intramembra-
nous ossification; however more recently numerous studies
have illustrated the advantages of bone formation through
endochondral ossification [25, 29, 41, 84, 91, 96, 101, 102].
Endochondral ossification is the method by which the
axial and long bones of the skeleton (the vast majority
of bones) are formed during embryogenesis [103] and has
many features common to bone regeneration after fracture
[104, 105] including activation of key signalling pathways
such as Indian hedgehog (IHH), parathyroid-related hor-
mone protein (PTHrP), wingless (wnt), and BMPs (although,
notably, the postnatal environment differs from that of the
developing embryo [104]). The process entails the condensa-
tion (clustering together through cell surface receptors and
adhesion molecules [106]) of chondrocytes, which secrete a
collagenous (type II) matrix rich in proteoglycans. Under the
control of two of the master regulators of bone development,
IHH, and PTHrP (see [103]), chondrocytes at the centre of the
proto-bone organ cease to proliferate and become enlarged
(hypertrophic), producing large amounts of type X collagen,
directing initial mineralisation [107] and vascularisation
through VEGF production, before undergoing apoptosis, to
leave a cartilage scaffold that will eventually be remodelled
into mature bone [103]. This strategy has been exploited for
bone regeneration; implantation of hypertrophic huBMSCs
in nude mice has been demonstrated to lead to the growth
of ectopic bone structures as a result of human cells playing
an active role of osteogenesis [25]. BMSCs embedded in 𝛽-
TCP scaffolds were able to generate frank bone in vivo, but
chondrogenic priming was necessary for the production of
bone + BM [96], while huBMSCs seeded on collagen type I
scaffolds induced towards endochondral ossification formed
not only bone organs, but also a fully functional BM which
was shown to sustain haematopoiesis in lethally irradiated
mice [84]. In a previous study cells that were not hypertrophic
at the time of implantation failed to generate bone and were
resorbed, indicating that the developmental stage is a critical
factor in dictating whether the implant will proceed to the
next stage [25, 108].
There are multiple advantages to implanting chondro-
genically primed cells: chondrocytes are more likely to sur-
vive the hypoxic in vivo environment [101]; they stimulate vas-
cularisation [101, 109] through secretion of VEGF [109] and
have been shown to increase bone formation in vivo through
BMP production [60]. Additionally, by selecting a stating
material which most closely matches the in vivo precursor to
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the tissue of interest and by guiding those cells through devel-
opmental stages using known markers, an intermediate form
of the tissue is generatedwhich “contains all the necessary and
sufficient instructive elements for its regeneration” [110].This
has obvious implications for the choice of cell source, since
a cell containing detectable genetic, epigenetic, proteomic
modifications which are optimal for a particular develop-
mental path is not only more likely to produce a higher
quality final product, but also likely to contain additional
characteristics which the limited and basic range of tests at
our disposal cannot gauge. That said, ADSCs, which had low
intrinsic bone-forming potential and produced no neo-bone
in their uninduced state, when chondrogenically primed
deposited a proteoglycan-rich cartilaginous matrix and were
able to generate a similar amount of bone as uninduced
BMSCs [62].This suggests that, by rerouting ADSCs through
endochondral ossification, a precursor state is created that
favours bone formation. It is noteworthy that despite the
successful rerouting of ADSCs, uninduced BMSCs achieved
better final results, perhaps reflecting intrinsic factors that
predispose them to bone formation [62, 75].
3.4. Considerations and Limitations of Mimicking Embryogen-
esis for BTE. While the adoption of processes which mimic
embryogenesis has demonstrated merit [84, 96], there are
salient physical, biochemical, mechanical, and immunolog-
ical differences between the developing embryo and amature
tissue microenvironment [60, 92, 104, 111]. Accordingly, we
must adjust the design of prospective implants to reflect
these differences [26]. Embryonic development occurs under
different immunological and inflammatory settings as well as
at a much smaller scale than in the adult; both of these factors
must be addressed if embryonic processes are to be harnessed
for the successful engineering of bone grafts.
Paracrine signalling gradients which function at the
embryonic scale are likely to be inefficient in a much larger
graft. Modular implants, comprising many smaller units,
may be utilised to overcome this hurdle (modular implants-
cellular sheets [112]) in addition to addressing some of the
limitations of mass transfer such as necrosis at the core of the
engineered tissue.
The immunological milieu controlling developmental
processes and the influx of cells at the embryonic stage of
bone growth remains to be fully elucidated. This is likely
to be a crucial step if we are to fully harness the poten-
tial of developmental engineering, as immune factors are
significant mediators of bone healing and regrowth [104],
which can result in retardation of healing if suppressed
[111, 113]. Interestingly, this last point serves to highlight
the differences between developmental processes underway
during embryogenesis and those involved in the adult: while
inflammation represents one of the main drivers of bone
repair [84, 111], it is absent during normal bone development.
In fact, the significance of interleukin-1𝛽 (IL-1𝛽) in the
revascularisation, mineralisation, and cartilage remodelling
activity of huBMSCs has been illustrated [111, 114].
In conclusion, the adoption of a developmental engineer-
ing paradigm for the regeneration of bone represents a poten-
tial method to mitigate the enormous hurdle presented by
largely unknown in vivo complexity. By generating precursor
organ germs based on observable in vitro elucidated markers
and allowing natural cues to orchestrate the development
of hypertrophic chondrocyte templates, it is foreseeable
that future bone repair strategies will achieve clinical use.
However, if we are to effectively utilise this technique, a
clearer more complete understanding of the biochemical and
mechanical forces at work in both the developing embryo and
the adult is required.
4. Implications of Scaffold Technology for
Cell versus Cell-Free Approaches
With the objective of repairing bone in a manner which
recalls natural healing processes, both cell-based and cell-
free methods have been utilised: both have advantages, but
currently cell-based therapeutic strategies are the status quo.
This usually comprises BMSCs which have been extracted
and either reinjected intraoperatively or cultured ex vivo for
several passages to generate many more cells which are then
reinjected in their current state, or, more commonly, seeded
on a three-dimensional scaffold material. Innovations in the
preparation of scaffold materials have added an additional
dimension to current BTE treatments and may pave the
way to standardized, off-the-shelf in vitro derived cell-free
products in clinical bone repair.
4.1. Cells or No Cells? Cell-based strategies, most often utilis-
ing BMSCs, have been shown to be more successful at stim-
ulating bone healing than cell-free approaches, resulting in
greater mineralisation, ossification, and increased angiogenic
potential [27–29, 48, 49]. These results are supported by data
showing cell-based techniques to be clinically advantageous
[115, 116]. However, the downsides to autologous cell-based
therapy are significant and can be prohibitive in some cases.
The rarity of BMSCs can be limiting to the point of rendering
cell extraction unfeasible (especially in the elderly and the ill)
and too few CFU-f within a BM extract will fail to generate
neo-bone tissue [72, 117]. Even in healthy individuals, cell
extraction requires an additional procedure which carries
added morbidity. Eliminating the need for extra surgery
has strongly motivated the development of intraoperative
techniques which, while avoiding the time-expensive and
laborious GMP handling of cells in the laboratory, are also
limited by the number of BMSCs available for reinjection.
Cell-free technologies have been proposed as an alterna-
tive to sidestepmany of the barriers associatedwith cell-based
techniques for bone-specific and other areas of tissue engi-
neering. A product which is available “off-the-shelf” follow-
ing decellularisation and sterilisation has obvious practical
advantages from a surgical perspective such as the reduction
of intrapatient variability and would allow the selection and
preparation of the implant prior to surgery. Additionally,
the implant can be recellularised with autologous BMSCs
prior to use if sufficient cells are available [29]. Also, a sterile
acellular product would be amenable to storage and thus
easily transported to areas of need where the resources for
10 Stem Cells International
preserving cell-based products might be lacking. All of these
reasons would act to increase the clinical uptake.
4.2. Decellularised ECM as a Biological Scaffold for BTE.
Many recent studies have attempted to mimic the inherent
complexity of the biological microenvironment, in terms of
architecture and biochemical constituents, through the use of
decellularised extracellular matrix (ECM) from a variety of
animal sources, both human [118, 119] and nonhuman [120,
121]. The latter option presents the possibility of benefiting
from existing slaughter processes to access a large volume of
material for decellularisation.The risk of zoonoses, especially
prion diseases, can be reduced by sourcing animals from
prion-free island populations [122, 123]. The use of cell lines
derived from either human or nonhuman animals to produce
a functional ECM that could subsequently be decellularised
presents the possibility of standardisation, reducing donor-
to-donor variability [9].
For the successful application of allogenic or xenogenic
sources, the implants must be effectively decellularised to
avoid a damaging immune response. The decellularisation
protocol represents a balancing act between preserving the
native biochemistry and microstructure and simultaneously
removing cells and other immunogenic materials. Decellu-
larisation is achieved primarily through physical/mechanical
(predominantly freeze-thaw), chemical (including detergent-
based methods), and enzymatic means coupled to wash
steps to remove debris (extensively reviewed in [124]). Any
treatment is almost certain to disrupt the native structure,
either physically or biochemically, and therefore strip away
many of the growth factors, cytokines, and inflammatory
factors harboured within the ECM.
With regard to bone engineering, the modern concept of
developmental engineering suggests that the endochondral
route provides the optimal template. Previously, hypertrophic
chondrocytes derived from human BMSCs were shown to
be remodelled and replaced by frank bone tissue, including
a functional haematopoietic compartment [24]. Accordingly,
decellularised hypertrophic cartilage has been used as a
template to stimulate the regeneration of bone material
through endochondral pathways, promoting the invasion
and proliferation of host cells [27–29]. Induced apoptosis
of hypertrophic chondrocytes has recently been proposed
to decellularise ECM for bone regeneration through the
retroviral transduction of a chemically inducible caspase-
9-bearing construct. This was shown to be superior to a
standard freeze-thaw protocol for the regeneration of bone.
Postapoptotic cartilage and implants containing live BMSCs,
but not nonhypertrophic cartilage, underwent extensive
remodelling and after 12 weeks in vivo tested positive for the
presence of a BM space, although implants containing live
cells outperformed the “apoptosed” tissue [27]. Elsewhere,
nonhypertrophic cartilage was shown to be inferior to hyper-
trophic constructs in a mouse femoral defect model, where
only the latter were successful in bridging the defect [28].
To date, the use of cell-free techniques has yet to demon-
strate equivalence to cell containing preparations. Devel-
opments in the methods used for decellularisation will
undoubtedly result in more effective scaffold materials,
due to greater retention of ECM-associated molecules with
simultaneous removal of cellular material, to yield bone
engineering products with off-the-shelf convenience, as well
as low-maintenance storage, and increased customisation.
Advances in scaffold preparation techniques, with or without
autologous cells, likely represent an area of keen future
research interest.
5. Conclusions
Intrinsic bone repair mechanisms are highly effective, but
in certain cases external intervention is required. In some
instances, BTE has been shown to provide clinical relief, but
improvement in BTE technologies is required to allow its
application to greater numbers of patients, particularly those
to whom traditional bone grafting procedures are unfeasible.
Recent strategies in bone repair and regeneration have
sought to embrace a developmental engineering approach,
following as closely as possible the natural processes of
bone development through the remodelling of hypertrophic
cartilage templates via endochondral ossification. The pre-
dominant use of BMSCs for bone formation following the
endochondral route reflects the role of the BM as the natural
reservoir of skeletal-tissue forming cells, namely, the SSC,
and illustrates their propensity to differentiate into skeletal
lineages.
BMSCs form bone + BM in vivo which is essential if cre-
ation of theHME is required.The factors (genetic, epigenetic,
proteomic, etc.) responsible for the predestination of BMSC
to form functional bone + BM are unknown, and we cannot
currently quantify the extent of these “unknown unknowns”
[125]. Likely a fraction of these factors driving BMSC to
form bone + BMwill also regulate additional steps in skeletal
development and remodelling allowing cells to correctly react
to autocrine and paracrine developmental signals. Until we
have a clearer understanding of the mechanisms underlying
bone development, BMSCs represent a more rational choice
for bone regeneration and repair if long-term propagation of
bone tissues (and haematopoietic cells) is desired.
This last point assumes the availability of autologous
BMSCs, which is not always the case. ADSCs are championed
by their proponents for their far greater accessibility and the
presence of greater numbers of CFU-f per unit volume than
that found in the BM. Clinical evidence of the efficacy of
ADSC-based therapy indicates that AT is an excellent source
for cells for the generation of bone tissue. Is this a question
of quantity over quality though? Where simple bone tissue
is called for rather than a functional bone-BM organ, it may
be the case that ADSC-derived bone is “good enough.” This,
coupled with the great advantages of using ADSCs, may be
enough to ensure the continued application and development
of ADSCs to bone repair.
Regardless of cell source, currently live cell-based
implants tend to be superior to cell-free and decellularised
alternatives at regenerating bone tissue. Recent advances in
decellularisation protocols are bringing the performance of
decellularised and devitalised tissues to ever greater levels,
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approaching that of vital implants, with the added value
of storage, transportation, and the possibility of allogenic
or xenogenic-derived grafts to circumgate the difficulties
in obtaining autologous cells for bone regeneration and
repair. Another valuable strategy to improve the results
of decellularised matrices is based on the intraoperative
recellularisation of the graft. In fact, it is nowadays possible
to recellularise a decellularised matrix with autologous bone
marrow cells, or fat-derived stromal and vascular cells. Future
research should be focused on developing effective and
sustainable clinically compliant bone regeneration strategies
that combine the efficacy of cell-based therapies with the
superior practical features of decellularised matrices.
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